Format

Send to

Choose Destination
See comment in PubMed Commons below
Biomed Res Int. 2014;2014:904341. doi: 10.1155/2014/904341. Epub 2014 Jul 6.

Cisplatin-based chemotherapy versus cetuximab in concurrent chemoradiotherapy for locally advanced head and neck cancer treatment.

Author information

1
Division of Hematology and Oncology, Department of Medicine, Taipei Veterans General Hospital, No. 201, Section 2, Shih-Pai Road, Taipei 112, Taiwan ; Faculty of Medicine, National Yang Ming University, No. 155, Section 2, Linong Street, Taipei 112, Taiwan ; Division of Hematology and Oncology, Department of Medicine, Cardinal Tien Hospital, No. 362, Zhongzheng Road, New Taipei City 231, Taiwan.
2
Faculty of Medicine, National Yang Ming University, No. 155, Section 2, Linong Street, Taipei 112, Taiwan ; Cancer Center, Taipei Veterans General Hospital, No. 201, Section 2, Shih-Pai Road, Taipei 112, Taiwan.
3
Faculty of Medicine, National Yang Ming University, No. 155, Section 2, Linong Street, Taipei 112, Taiwan ; Division of Hematology and Oncology, Department of Medicine, Show Chwan Memorial Hospital, No. 542, Section 1, Zhongshan Road, Changhua City, Changhua County 500, Taiwan.
4
Faculty of Medicine, National Yang Ming University, No. 155, Section 2, Linong Street, Taipei 112, Taiwan ; Department of Otolaryngology, Taipei Veterans General Hospital, No. 201, Section 2, Shih-Pai Road, Taipei 112, Taiwan.
5
Division of Hematology and Oncology, Department of Medicine, Taipei Veterans General Hospital, No. 201, Section 2, Shih-Pai Road, Taipei 112, Taiwan ; Faculty of Medicine, National Yang Ming University, No. 155, Section 2, Linong Street, Taipei 112, Taiwan.
6
Division of Hematology and Oncology, Department of Medicine, Taipei Veterans General Hospital, No. 201, Section 2, Shih-Pai Road, Taipei 112, Taiwan ; Institute of Clinical Medicine, National Yang Ming University, No. 155, Section 2, Linong Street, Taipei 112, Taiwan.

Abstract

BACKGROUND AND PURPOSE:

This study aimed to analyze survival, clinical responses, compliance, and adverse effects in locally advanced head and neck cancer (LAHNC) patients treated with split-dose cisplatin-based concurrent chemoradiation therapy (SD-CCRT) or cetuximab with concurrent radiation therapy (BioRT).

MATERIALS AND METHODS:

We retrospectively evaluated 170 LAHNC patients diagnosed between January 1, 2009, and July 31, 2012: 116 received CCRT and 54 received BioRT.

RESULTS:

Complete response rates were similar in the SD-CCRT and BioRT groups (63.8% versus 59.3%; P = 0.807), and locoregional relapse rates were 18.1% and 13.0%, respectively (P = 0.400). The 3-year relapse-free survival rate was 65.8% in the SD-CCRT group and 65.5% in the BioRT group, respectively (P = 0.647). The 3-year overall survival rate was 78.5% in the SD-CCRT group and 70.9% in the BioRT group, respectively (P = 0.879). Hematologic side effects were significantly more frequent in the SD-CCRT than in the BioRT group. Mucositis frequency was similar.

CONCLUSIONS:

Primary SD-CCRT and BioRT both showed good clinical response and survival. Hematologic toxicities were more frequent, but tolerable, in the SD-CCRT group. Both groups showed good compliance.

PMID:
25110705
PMCID:
PMC4109223
DOI:
10.1155/2014/904341
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Hindawi Publishing Corporation Icon for PubMed Central
    Loading ...
    Support Center